The T2T strategy is superior in obtaining gout remission compared to the T2S strategy, and cost-effective.
ID
Bron
Verkorte titel
Aandoening
Gout
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The GO TEST OVERTURE study aims to demonstrate the superiority of the T2T management strategy
over a T2S approach in terms of clinical remission of gout symptoms.
Achtergrond van het onderzoek
Urate Lowering Therapy (ULT) plays an important role in the management of gout, however it can be implemented through different strategies. In the absence of high-quality evidence, international guidelines disagree which management strategy is optimal. The Gout TrEatment STrategy project (GO TEST) aims to compare clinical outcomes and cost-effectiveness of the Treat to Target (T2T) versus the Treat to avoid Symptoms (T2S) management strategies at two different points of the gout patients 'journey. The research protocol describes the GO TEST OVERTURE study in which gout patients not currently receiving ULT will be randomized to T2T or T2S and followed up for two years.
Doel van het onderzoek
The T2T strategy is superior in obtaining gout remission compared to the T2S strategy, and cost-effective.
Onderzoeksopzet
Baseline, T1 (1 year follow-up visit), T2 ( 2 year follow-up visit)
Onderzoeksproduct en/of interventie
T2T strategy, starting ULT with the goal of obtaining clinical remission and a SUA target
<0.36mmol/ or <0.30 mmol/l, intensifying ULT until targets are reached.
Algemeen / deelnemers
Wetenschappers
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
To be eligible to participate in this study, a subject must meet all the following criteria:
• Patients with a clinical diagnosis of gout and/or fulfilling the 2015 ACR-EULAR criteria
• Indication for ULT
• No current use of ULT
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
A potential participant will be excluded from the study if one or more of the following criteria have been
met:
• A strong Contraindication for allopurinol, benzbromarone AND febuxostat
• eGFR < 30ml/minute
• Insufficient mastery of Dutch language to fill out questionnaires
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Toelichting
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL9575 |
| CCMO | NL74873.091.20 |
| OMON | NL-OMON55282 |